*ST Sailon: Announcement on the Subsidiary Obtaining the Drug Registration Certificate for Injectable Tedizolid Phosphate
Securities code: 002898 Securities abbreviation: *ST Sailon Announcement number: 2026-058
Sailong Pharmaceutical Group Co., Ltd.
Announcement on the Subsidiary Obtaining the Drug Registration Certificate for Tedizolid Phosphate for Injection
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete, and contains no false records, misleading statements or major omissions.
Hunan Sailon Pharmaceutical Co., Ltd., a wholly-owned subsidiary of Sailon Pharmaceutical Group Co., Ltd. (hereinafter referred to as the "Company"), has recently obtained the Drug Registration Certificate for Tedizolid Phosphate for Injection approved and issued by the State Food and Drug Administration. The relevant information is now announced as follows:
1. Basic information on drugs
Drug name: Tedizolid phosphate for injection
Dosage form: injection
Specifications: 200mg
Registration classification: Chemicals Class 4
Certificate number: 2026S01616
Drug registration standard number: YBH12142026
Drug approval number: National Drug Approval Number H20264393
Drug approval number is valid until May 18, 2031
Approval conclusion: According to the "Drug Administration Law of the People's Republic of China" and relevant regulations, after review, this product meets the relevant requirements for drug registration, the registration is approved, and a drug registration certificate is issued. The quality standards, instructions, labels and production processes are as attached. Pharmaceutical manufacturing enterprises must comply with the requirements of pharmaceutical quality management regulations before they can produce and sell drugs.
2. Other related information about drugs
Tedizolid phosphate for injection is used to treat acute bacterial skin and skin and soft tissue infections.
3. Risk warning
The approval of the above-mentioned drugs has further enriched the company's preparation varieties. The specific sales situation depends on various factors such as internal and external environmental changes, and there is a certain degree of uncertainty. The company will promptly fulfill its information disclosure obligations based on subsequent progress. Investors are advised to make prudent decisions and pay attention to preventing investment risks.
Announcement is hereby made.
The Board of Directors of Sailon Pharmaceutical Group Co., Ltd.
May 22, 2026